Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Quan Man

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8152-7477; OpenAlex author ID A5029788983. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2023: 8 papers · 2024: 2 papers · 2025: 1 paper

Papers 11

  1. Integrated pretreatment stratification system for pancreatic cancer: combining anatomical resectability and tumor biological parameters. Co-author DOI 10.20892/j.issn.2095-3941.2025.0213↗
  2. Nomogram model for predicting early recurrence for resectable pancreatic cancer: A multicenter study. Co-author DOI 10.1097/md.0000000000037440↗
  3. Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0363↗
  4. Biological risk based on preoperative serum CA19-9 and histological grade predicts prognosis and improves accuracy of classification in patients with pancreati… Co-author DOI 10.1002/cnr2.1911↗
  5. Prognostic nutritional score based on pretreatment lymphocyte, platelet, and prealbumin predicts prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/jso.27362↗
  6. A new staging system for postoperative prognostication in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2023.107589↗
  7. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. Co-author DOI 10.1186/s13046-023-02671-8↗
  8. Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma. First author DOI 10.20892/j.issn.2095-3941.2022.0569↗
  9. Impact of preoperative CA19-9 and histology grade on prognosis of pancreatic ductal adenocarcinoma and its value in TNM stage Co-author DOI 10.21203/rs.3.rs-2653528/v1↗
  10. Biological risk based on preoperative serum CA19-9 and histology grade predicts prognosis in patients with pancreatic cancer Co-author DOI 10.22541/au.168681252.23358138/v1↗
  11. Presence of tumor deposits is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author PMID 37293176↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuexiang Liang · 9 shared papers, 2023–2025 · strength 1.95
  2. Shaofei Chang · 9 shared papers, 2023–2025 · strength 1.95
  3. Song Gao · 5 shared papers, 2023–2025 · strength 1.02
  4. Tiansuo Zhao · 5 shared papers, 2023–2025 · strength 0.98
  5. Jihui Hao · 5 shared papers, 2023–2025 · strength 0.92
  6. Yiping Zou · 3 shared papers, 2023–2025 · strength 0.62
  7. Haorui Li · 3 shared papers, 2023 · strength 0.61
  8. Song Gao · 2 shared papers, 2024–2025 · strength 0.44
  9. Xiuchao Wang · 2 shared papers, 2023–2025 · strength 0.36
  10. Yongjie Xie · 2 shared papers, 2023 · strength 0.30
  11. Tianxing Zhou · 2 shared papers, 2023 · strength 0.30
  12. Jing Liu · 2 shared papers, 2023 · strength 0.30
  13. Junjin Wang · 1 shared paper, 2024 · strength 0.26
  14. Jun Yu · 1 shared paper, 2025 · strength 0.23
  15. Guannan Sheng · 1 shared paper, 2024 · strength 0.21
  16. Shengyu Yang · 1 shared paper, 2023 · strength 0.13
  17. Danqi Fu · 1 shared paper, 2023 · strength 0.13
  18. Xiufeng Zhang · 1 shared paper, 2023 · strength 0.13
  19. Chongbiao Huang · 1 shared paper, 2023 · strength 0.13
  20. Wenna Jiang · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.